Site icon almostadoctor

PSA – Prostate Specific Antigen

Prostate gland

Prostate gland

Introduction

Prostate specific antigen (PSA) is a glycoprotein enzyme which is secreted by epithelial cells of the prostate. Levels of PSA rise with prostate inflammation which can be due to:

The use of PSA blood tests can be controversial and advice may be conflicting. As of 2021 it is generally NOT advised screen patients for prostate cancer with regular PSA testing, instead reserving it for those with a strong family history, of symptoms of prostatic enlargement.

There is also not a specific widely accepted cut-off level for what constitutes as a ‘raised’ PSA level. PSA naturally rises with age. Typically a level of <3.5ug/L would be considered normal, but in older patients higher levels may still be acceptable (up to 9 in new aged 80+) . Tracking the pattern of the level of PSA may be more appropriate. It is also possible to test for bound vs free PSA levels in the blood. Those with a free PSA percentage of >20% are generally considered to be low risk for prostate cancer. Those with a low percentage of <10% are very high risk for prostate cancer. Levels of 10-20% are considered indeterminate.

When to screen

The RACGP in Australia recommends discussing a man’s individual risk before screening, and offering patients a choice of annual screening (or not) after this discussion. This advice applies to patients aged 50-69. Routine screening is not recommended.

Those with lower urinary tract symptoms (LUTS) should have thorough urological history, examination and PSA testing – this is NOT screening in these circumstances but rather investigation of abnormal symptoms.

Those with a family history of prostate cancer particularly before the age of 55 should be considered for screening.

Pros and cons of screening

For every 1000 men aged 50-69 screened for 11 years:

WITHOUT screening WITH screening
5 men will die from prostate cancer 4 will die from prostate cancer, one possibly will be saved
190 will die from other causes 190 will die form other causes
55 men will be alive with symptomatic prostate cancer 55 men will be alive with symptomatic prostate cancer
  87 will have a false positive PSA discovered upon biopsy of prostate
  28 will require health care or hospitalisation for side effects of the biopsy
  25 will have unnecessary treatment for prostate cancer
  10 men will have incontinence or erectile dysfunction or a bowel complication as a result of the biopsy
  1 in 2000 will die from MI as a result of unnecessary treatment or other complication

 

As demonstrated above, the benefits are not clear. In my clinical experience, most men decide against prostate screening when presented with this information. The RACGP provides a handout for patients with this and more information to assist in helping them to make an informed decision. PSA screening is a good example of shared decision making between doctor and patient in modern medical practice.

When PSA is raised

Repeat the test in two weeks with free and bound PSA levels.

Consider a prostate examination (DRE – digital rectal examination) if levels of PSA remain raised.

When examining the prostate:

Consider the causes of raised PSA

References

Related Articles

Exit mobile version